The role of AMP-Activated protein kinase in quercetin-induced apoptosis of HL-60 cells

Acta Biochimica et Biophysica Sinica

Volumn 46, Issue 5, 2014, Pages 394-400

  Xiao, Jie ^a   Niu, Guomin ^b   Yin, Songmei ^a   Xie, Shuangfeng ^a   Li, Yiqing ^a   Nie, Danian ^a   Ma, Liping ^a   Wang, Xiuju ^a   Wu, Yudan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b People's Hospital in Nanhai District of Foshan City   (China)

Author keywords

AMP Activated protein kinase; cyclooxygenase 2; leukemia; quercetin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; QUERCETIN;

APOPTOSIS; DRUG EFFECTS; FLOW CYTOMETRY; HL 60 CELL LINE; HUMAN; METABOLISM; PHYSIOLOGY;

AMP-ACTIVATED PROTEIN KINASES; APOPTOSIS; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; QUERCETIN;

EID: 84899856024     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmu014     Document Type: Article

References (26)

1. Niu G, Yin S, Xie S, Li Y, Nie D, Ma L and Wang X, et al. Quercetin induces apoptosis by activating caspase-3 and regulating Bcl-2 and cyclooxygenase-2 pathways in human HL-60 cells. Acta Biochim Biophys Sin (Shanghai) 2011, 43: 30-37.
2. Russo GL, Russo M, Spagnuolo C, Tedesco I, Bilotto S, Iannitti R and Palumbo R. Quercetin: a pleiotropic kinase inhibitor against cancer. Cancer Treat Res 2014, 159: 185-205.
3. Yuan Z, Long C, Junming T, Qihuan L, Youshun Z and Chan Z. Quercetin-induced apoptosis of HL-60 cells by reducing PI3K/Akt. Mol Biol Rep 2012, 39: 7785-7793.
4. Sakao K, Fujii M and Hou DX. Acetyl derivate of quercetin increases the sensitivity of human leukemia cells toward apoptosis. Biofactors 2009, 35: 399-405.
5. Yu CS, Lai KC, Yang JS, Chiang JH, Lu CC, Wu CL and Lin JP, et al. Quercetin inhibited murine leukemia WEHI-3 cells in vivo and promoted immune response. Phytother Res 2010, 24: 163-168.
6. Rattan R, Giri S, Singh AK and Singh I. 5-Aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-Activated protein kinase. J Biol Chem 2005, 280: 39582-39593.
7. Hardie DG. AMP-Activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007, 8: 774-785.
8. Lee YK, Park SY, Kim YM, Lee WS and Park OJ. AMP kinase/ cyclooxygenase-2 pathway regulates proliferation and apoptosis of cancer cells treated with quercetin. Exp Mol Med 2009, 41: 201-207.
9. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A and Bignell G, et al. A serine/threonine kinase gene defective in Peutz- Jeghers syndrome. Nature 1998, 391: 184-187.
10. Kim CJ, Cho YG, Park JY, Kim TY, Lee JH, Kim HS and Lee JW, et al. Genetic analysis of the LKB1/STK11 gene in hepatocellular carcinomas. Eur J Cancer 2004, 40: 136-141.
11. Fan D, Ma C and Zhang H. The molecular mechanisms that underlie the tumor suppressor function of LKB1. Acta Biochim Biophys Sin (Shanghai) 2009, 41: 97-107.
12. Green AS, Chapuis N, Maciel TT, Willems L, Lambert M, Arnoult C and Boyer O, et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTORdependent oncogenic mRNA translation. Blood 2010, 116: 4262-4273.
13. Berstein LM, Boyarkina MP and Teslenko SY. Familial diabetes is associated with reduced risk of cancer in diabetic patients: a possible role for metformin. Med Oncol 2012, 29: 1308-1313.
14. Sengupta TK, Leclerc GM, Hsieh-Kinser TT, Leclerc GJ, Singh I and Barredo JC. Cytotoxic effect of 5-Aminoimidazole-4-carboxamide-1-beta- 4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer 2007, 6: 46.
15. Park WS, Moon YW, Yang YM, Kim YS, Kim YD, Fuller BG and Vortmeyer AO, et al. Mutations of the STK11 gene in sporadic gastric carcinoma. Int J Oncol 1998, 13: 601-604.
16. Dong SM, Kim KM, Kim SY, Shin MS, Na EY, Lee SH and Park WS, et al. Frequent somatic mutations in serine/threonine kinase 11/ Peutz-Jeghers syndrome gene in left-sided colon cancer. Cancer Res 1998, 58: 3787-3790.
17. Lee YK and Park OJ. Regulation of mutual inhibitory activities between AMPK and Akt with quercetin in MCF-7 breast cancer cells. Oncol Rep 2010, 24: 1493-1497.
18. Kim HJ, Kim SK, Kim BS, Lee SH, Park YS, Park BK and Kim SJ, et al. Apoptotic effect of quercetin on HT-29 colon cancer cells via the AMPK signaling pathway. J Agric Food Chem 2010, 58: 8643-8650.
19. Ahn J, Lee H, Kim S, Park J and Ha T. The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways. Biochem Biophys Res Commun 2008, 373: 545-549.
20. Zhang H, Li N, Wu J, Su L, Chen X, Lin B and Luo H. Galangin inhibits proliferation of HepG2 cells by activating AMPK via increasing the AMP/ TAN ratio in a LKB1-independent manner. Eur J Pharmacol 2013, 718: 235-244.
21. Fogarty S and Hardie DG. C-terminal phosphorylation of LKB1 is not required for regulation of AMP-Activated protein kinase, BRSK1, BRSK2, or cell cycle arrest. J Biol Chem 2009, 284: 77-84.
22. Xie Z, Dong Y, Scholz R, Neumann D and Zou MH. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-Activated protein kinase in endothelial cells. Circulation 2008, 117: 952-962.
23. Park IJ, Lee YK, Hwang JT, Kwon DY, Ha J and Park OJ. Green tea catechin controls apoptosis in colon cancer cells by attenuation of H2O2- stimulated COX-2 expression via the AMPK signaling pathway at low-dose H2O2. Ann N Y Acad Sci 2009, 1171: 538-544.
24. Hwang JT, Lee YK, Shin JI and Park OJ. Anti-inflammatory and anticarcinogenic effect of genistein alone or in combination with capsaicin in TPA-treated rat mammary glands or mammary cancer cell line. Ann N Y Acad Sci 2009, 1171: 415-420.
25. Xavier CP, Lima CF, Rohde M and Pereira-Wilson C. Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation. Cancer Chemother Pharmacol 2011, 68: 1449-1457.
26. Jakubowicz-Gil J, Langner E, Ba?dziul D, Wertel I and Rzeski W. Silencing of Hsp27 and Hsp72 in glioma cells as a tool for programmed cell death induction upon temozolomide and quercetin treatment. Toxicol Appl Pharmacol 2013, 273: 580-589